Mark Stein retweeted
JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1
@ASCO @myESMO @AACR @kidneycan @DanaFarber_GU @OncoAlert
Mark Stein retweeted
@DrScottTagawa leading an expert panel on navigating prostate cancer treatment. @Katie_Spina, James Kashanian, Doug Scherr
Mark Stein retweeted
Excited to share our new study in @JCOPO_ASCO examining the genomic landscape of early-onset GI cancers using >53,000 tumors from @AACR Project GENIE. @columbiacancer
ascopubs.org/doi/10.1200/PO-…
Mark Stein retweeted
Join us November 20 for the Genitourinary Oncology Symposium! A day bringing together experts across urology, medical oncology, radiation oncology, and more to examine what’s changing across prostate, bladder, and kidney cancer care.
Sign up now: eventleaf.com/Attendee/Atten…
Mark Stein retweeted
Great to see this article about the drug TIC10/ONC201 discovered in my academic lab in 2007 after we performed a chemical library screen while we were at @Penn.
We’ve learned much about its mechanism of action over the years and it has been the thrill of a lifetime to see it get a first ever approval by the @US_FDA on August 6, 2025 for some of the most aggressive middle of the brain tumors with H3K27M mutation.
The discovery followed an earlier discovery that the tumor suppressor p53 links to our innate immune system through control of TRAIL Death Receptor 5 in 1997, work done while my lab was supported by the Howard Hughes Medical Institute (@hhmi_science).
The story is about basic science to clinical impact through precision oncology but there is still much more to be done to help patients.
linkedin.com/posts/wafike_gr…
@AACR @AmericanCancer @ASCO @AACI_Cancer @WIN_Consortium @Dr_R_Kurzrock @VivekSubbiah @SewantiLimaye @DrRoyHerbst @RoyJensenMD @DrJoannSweasy @DrPhilKantoff @DrRobWinn @billdahutmd @jrgralow @AACRPres
@AshleySumrallMD @SeanLawler20 @NCIDirector @BrownUniversity @bcarneiro7 @lillian_siu
Mark Stein retweeted
Radiographic progression without PSA progression: a major issue with a poor prognosis. Identified in two phase 3 trials in mHSPC and nmCRPC in setting of ADT/ARPI. Routing imaging thus recommended! ascopubs.org/doi/10.1200/JCO… @DukeCancer @DukeGUCancer @PCFnews @JCO_ASCO
Mark Stein retweeted
Here's our latest, where we explored how to augment LLMs with constantly evolving precision oncology knowledge (h/t @moalmanac), followed by collaboration with medical oncologists to test their queries - congrats Helena Jun, et al!
Mark Stein retweeted
Fantastic event dedicated to education and the impact of prostate cancer on our patients, hosted by @WeillCornell @WCMGUcancer @MSK_DeptOfMed @MSKCancerCenter @columbiacancer @nyphospital, at the NY Academy of Medicine. Sign up today! prostatesummit.org
Don’t miss the 7th annual #NYCProstateSummit dedicated to educating and empowering patients and loved ones impacted by #ProstateCancer hosted by @WeillCornell @nyphospital @MSKCancerCenter and @ColumbiaMed. All are welcome to attend, but RSVP is required: prostatesummit.org
Mark Stein retweeted
‼️A #clinicaltrial led by Dr. Mark Stein is showing remarkable results against aggressive prostate cancers. Even at low doses, the immune-stimulating drug pasritamig shrank tumors in many late-stage patients. @ColumbiaMed Read more ➡️ @JNJNews cancer.columbia.edu/news/ope…
Mark Stein retweeted
A new PET biomarker in men with high-risk metastatic castration-resistant prostate cancer. Total tumor volume prognostic for overall survival and predictive for benefit of Lu-177 PSMA-617.
Great data from @ANZUPtrials ENZA-P led by @drlouiseemmett
authors.elsevier.com/c/1lWie…~
Another 🇦🇺 @TheLancetOncol #theranostics
Mark Stein retweeted
Excited to share a new paper: tinyurl.com/49u5e6by @CellCellPress: a framework to accelerate variant classification, diagnosis & treatment of immune disorders & genetic disorders more broadly. Led by superstar, juggernaut & future dermatologist @zwalsh96
Mark Stein retweeted
Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer
aacrjournals.org/clincancerr…
Research has shown that around 30% of advanced #ProstateCancer patients have Homologous Recombination / DNA Damage Repair (HRR) alterations (HRRalt), which have been linked to a poorer outlook in metastatic castrate-resistant prostate cancer.
This study, the largest of its kind, investigated the impact of HRRalt on patients with metastatic hormone-sensitive prostate cancer (mHSPC). Analyzing data from 637 U.S. patients, researchers found that those with HRRalt (28.4% of the group) had a significantly shorter time to castrate-resistance (TTCR) when treated with either an androgen receptor pathway inhibitor or a taxane, compared to patients without HRRalt.
While overall survival also trended less favorably in patients with HRRalt, these findings highlight the potential importance of HRRalt in mHSPC prognosis and could help guide future clinical trials and patient discussions.
@chadihcmd
@RyonGraf
@ziremozay
@ggebraelmd
@nsayeghmd
@maughanonc
@EAntonarakis
@neerajaiims
@umangtalking
@OncoAlert
@Silke_Gillessen @AOmlin
@bavilima @nataliagandur
Mark Stein retweeted
Stage II seminoma: what’s best? JCO 2025.
Review compares standard chemo/RT vs novel strategies: RPLND, de-escalated chemo, combo therapy.
👨⚕️ Men with IIA/IIB seminoma, LN ≤3 cm
✅ All: >90% cure
🔄 RPLND: relapse 10–30%, avoids chemo/RT in ~70%
1/2 @OncoAlert
Mark Stein retweeted
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
ascopubs.org/doi/10.1200/JCO…
This phase I trial of pasritamig, a novel bispecific T-cell–engaging antibody targeting KLK2 in metastatic castration-resistant #prostateCancer , demonstrated a manageable safety profile with mostly low-grade adverse events and minimal cytokine release syndrome.
Showed promising preliminary antitumor activity, including a 42.4% PSA response rate and a median radiographic progression-free survival of 7.85 months, supporting further clinical development.
@drmnstein
@DebbieRobbrecht
@DogerStart
@MikeSchweizerMD
@EmilianoCalvo_
@meavdongen
@DrDariaGaut
Ping @OncoAlert 🚨
@Silke_Gillessen @AOmlin
@nataliagandur @bavilima
Mark Stein retweeted
Phase I trial combines ONC-392 with Lutetium-177 for #ProstateCancer. David Wise, MD, PhD @nyulangone joins @TiansterZhang @UTSWMedCenter discussing this phase I trial of ONC-392 + 177Lu-PSMA, targeting Tregs to overcome resistance after lutetium therapy. Early results: safe, no added toxicity—aiming for deeper, longer-lasting responses. #WatchNow > bit.ly/3SEkHCt
Mark Stein retweeted
📢 #ASCO25 | mCRPC Ph. I | KLK2×CD3 bispecific pasritamig: First-in-human (n = 174) shows PSA50 42.4%, median rPFS 6.8 m; G≥3 TRAEs 9.2%, no CRS > G1. by Dr. #CapucineBaldini from @GustaveRoussy et al. Full abstract → [shorturl.at/meFe4]
@ASCO @ASCOPost @JCO_ASCO
@neerajaiims @montypal @bergsa83
@GlopesMd @VivekSubbiah @OncoAlert
@tompowles1 @OncBrothers @medicalwatchBC @yekeduz_emre
@CParkMD @Silke_Gillessen @PGrivasMDPhD
@TwoOncDocs @OncBrothers @Larvol @nataliagandur @crisbergerot @DrDanielHeng
@TiansterZhang @HammersMD @sonpavde @drenriquegrande @scserendipity1
@BraunMDPhD @Uromigos @AminNassarMD
@ZiadBakouny @DrRanaMcKay @NazliDizman
Mark Stein retweeted
Just in from @ASCO #ASCO25 👉📢 Finally a T-cell engager in #prostatecancer mCRPC with minimal CRS syndrome (only grade 1, all outpatient dosing) and promising efficacy👇 Congrats #drbaldini @drmnstein and team @JCO_ASCO @OncoAlert @urotoday @PCF_Science
Mark Stein retweeted
From Challenges to Cures: Improving Outcomes in Patients With Renal Cell Carcinoma | JCO Oncology Practice ascopubs.org/doi/10.1200/OP-…
